Aurdan Capital Management LLC Takes Position in Cencora, Inc. (NYSE:COR)

Aurdan Capital Management LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 37,518 shares of the company's stock, valued at approximately $8,429,000. Cencora accounts for approximately 3.2% of Aurdan Capital Management LLC's portfolio, making the stock its 9th biggest holding.

Other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Cencora by 0.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock worth $1,990,542,000 after buying an additional 78,066 shares during the period. Bank of America Corp DE increased its position in shares of Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after purchasing an additional 1,994,256 shares in the last quarter. Boston Partners raised its holdings in shares of Cencora by 2.6% in the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after buying an additional 125,611 shares during the last quarter. Geode Capital Management LLC grew its holdings in Cencora by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock valued at $969,471,000 after buying an additional 130,213 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after acquiring an additional 550,246 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 1.1%

NYSE COR traded up $3.11 during mid-day trading on Friday, reaching $293.80. The stock had a trading volume of 324,459 shares, compared to its average volume of 1,535,249. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a fifty day moving average price of $284.36 and a 200 day moving average price of $258.25. Cencora, Inc. has a 1 year low of $218.32 and a 1 year high of $309.35. The stock has a market cap of $56.94 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the business earned $3.80 earnings per share. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on COR. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Robert W. Baird lifted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Finally, Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. This represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,223 shares of company stock valued at $12,369,767. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.